and , -- The Florida Institute for the Commercialization of Public Research (the Florida Institute) announced today that Aviana Molecular Technologies, LLC, an -based point of care (POC) diagnostics company with technology licensed from the , received follow-on second round financing after achieving significant development milestones since its initial funding. The Florida Institute supports new company creation based on publicly-funded research, and bridges early funding gaps for companies spinning out of Florida-based universities and research institutions.
Aviana is developing miniaturized biosensors capable of attaching to a smartphone/smart device through Bluetooth or other wireless connections. The company received initial funding from the Institute through its Florida Technology Seed Capital Fund in and since then has closed in additional investment from angels, consisting primarily of physicians. Aviana has hired additional employees, and completed initial functioning systems development. The capital raised will allow the company to optimize the system and obtain preliminary data on biological markers of interest.
"Our mission is to provide highly sensitive and specific diagnostic capability to anyone with a smart device: physician, medical technologist, patient, public health worker while connecting seamlessly (with adequate protections) to the internet," said , MD, Aviana's President and Chief Executive Officer. "Recent investments will allow us to continue development and expand our sensors for monitoring human health. We plan on working towards milestones that will allow us to obtain follow on funding for a full development of our technology."
"Aviana's technology is simple, adaptable, and potentially can be used as a point of care diagnostic platform for any number of biomarkers or infectious agents," said , MD, Florida Institute Chief Executive Officer. "The Institute looks forward to supporting Aviana as they continue to develop this cutting-edge technology."
About the Florida Institute